Karl Swedberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5438586/publications.pdf

Version: 2024-02-01

264 papers	48,263 citations	4960 84 h-index	1634 215 g-index
273 all docs	273 docs citations	273 times ranked	24416 citing authors

#	Article	IF	Citations
1	Angiotensinâ€“Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine, 2014, 371, 993-1004.	27.0	5,052
2	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, The, 2003, 362, 777-781.	13.7	2,584
3	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 2011, 364, 11-21.	27.0	2,491
4	Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine, 2003, 349, 1893-1906.	27.0	2,240
5	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet, The, 2010, 376, 875-885.	13.7	2,119
6	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal, 2005, 26, 1115-1140.	2.2	1,986
7	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, The, 2003, 362, 767-771.	13.7	1,978
8	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008â€¡. European Journal of Heart Failure, 2008, 10, 933-989.	7.1	1,893
9	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, The, 2003, 362, 759-766.	13.7	1,752
10	Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, The, 2003, 362, 7-13.	13.7	1,664
11	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, The, 2003, 362, 772-776.	13.7	1,623
12	Person-Centered Care â€" Ready for Prime Time. European Journal of Cardiovascular Nursing, 2011, 10, 248-251.	0.9	1,151
13	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. European Heart Journal, 2013, 34, 1404-1413.	2.2	921
14	Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet, The, 2010, 376, 886-894.	13.7	769
15	Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients. Circulation, 2005, 112, 3738-3744.	1.6	678
16	Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. European Heart Journal, 2005, 26, 1303-1308.	2.2	564
17	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61.	1.6	552
18	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 2008, 29, 1377-1385.	2.2	549

#	Article	IF	Citations
19	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation, 2007, 116, 1482-1487.	1.6	528
20	Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology, 2006, 47, 1997-2004.	2.8	507
21	Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine, 2013, 368, 1210-1219.	27.0	462
22	PROLONGATION OF SURVIVAL IN CONGESTIVE CARDIOMYOPATHY BY BETA-RECEPTOR BLOCKADE. Lancet, The, 1979, 313, 1374-1376.	13.7	377
23	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensinâ€converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). European Journal of Heart Failure, 2013, 15, 1062-1073.	7.1	358
24	Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.	27.0	355
25	Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. Circulation, 2004, 110, 2618-2626.	1.6	347
26	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal, 2015, 36, 1990-1997.	2.2	335
27	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation, 2020, 141, 352-361.	1.6	335
28	The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. European Heart Journal, 2014, 35, 2001-2009.	2.2	274
29	Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC: Heart Failure, 2018, 6, 489-498.	4.1	272
30	Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal, 2011, 32, 2507-2515.	2.2	264
31	A trial to evaluate the effect of the sodiumâ€“glucose coâ€transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPAâ€HF). European Journal of Heart Failure, 2019, 21, 665-675.	7.1	264
32	Effects of person-centred care in patients with chronic heart failure: the PCC-HF study. European Heart Journal, 2012, 33, 1112-1119.	2.2	261
33	Risk Related to Preâ€“Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	260
34	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 333-340.	11.4	258
35	Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. Journal of the American College of Cardiology, 2012, 59, 1598-1603.	2.8	249
36	Decreasing one-year mortality and hospitalization rates for heart failure in Sweden Data from the Swedish Hospital Discharge Registry 1988 to 2000. European Heart Journal, 2004, 25, 300-307.	2.2	234

#	Article	IF	Citations
37	Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?. Journal of the American College of Cardiology, 2012, 59, 1938-1945.	2.8	233
38	Efficacy of personâ€centred care as an intervention in controlled trials â€“ a systematic review. Journal of Clinical Nursing, 2013, 22, 456-465.	3.0	215
39	Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function. Journal of the American College of Cardiology, 2013, 62, 1585-1593.	2.8	204
40	Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology, 2013, 102, 11-22.	3.3	199
41	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal, 2015, 36, 2576-2584.	2.2	187
42	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to <scp>CHARM</scp>â€Preserved. European Journal of Heart Failure, 2014, 16, 33-40.	7.1	186
43	Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. American Journal of Cardiology, 1984, 54, 783-786.	1.6	179
44	Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1992, 70, 479-487.	1.6	176
45	Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. European Heart Journal, 2011, 32, 2395-2404.	2.2	175
46	Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. European Heart Journal, 2005, 26, 2706-2713.	2.2	172
47	Symptoms in Patients With Heart Failure are Prognostic Predictors: Insights From COMET. Journal of Cardiac Failure, 2005, 11, 288-292.	1.7	168
48	Differential Impact of Heart Failure WithÂReduced Ejection Fraction onÂMenÂandÂWomen. Journal of the American College of Cardiology, 2019, 73, 29-40.	2.8	168
49	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 2017, 38, 1132-1143.	2.2	160
50	Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure. Journal of the American College of Cardiology, 2008, 52, 1640-1648.	2.8	159
51	Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. European Heart Journal, 2005, 26, 2259-2268.	2.2	154
52	Î²-Blockers in Chronic Heart Failure. Circulation, 2003, 107, 1570-1575.	1.6	150
53	Health-Related Quality of Life Outcomes in PARADIGM-HF. Circulation: Heart Failure, 2017, 10, .	3.9	150
54	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European Heart Journal, 2012, 33, 2782-2795.	2.2	148

#	Article	IF	Citations
55	Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGMâ€HF</scp>). European Journal of Heart Failure, 2014, 16, 817-825.	7.1	148
56	Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2012, 59, 1785-1795.	2.8	146
57	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. JAMA Cardiology, 2017, 2, 79.	6.1	143
58	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. Circulation, 2016, 133, 2254-2262.	1.6	142
59	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, e002744.	3.9	130
60	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGMâ€HF trial. European Journal of Heart Failure, 2019, 21, 337-341.	7.1	129
61	Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal, 2012, 33, 2813-2820.	2.2	126
62	Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NTâ€proBNP Guided Management of Heart Failure â€“ SIGNALâ€HF (Swedish Intervention study â€“ Guidelines) Tj ETQq0 0 0 rgBT /Ove	1.1	125
63	Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 590-595.	3.9	123
64	Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 of Heart Failure, 2009, 11, 1143-1151.	7.1	118
65	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. Journal of the American College of Cardiology, 2015, 66, 2059-2071.	2.8	118
66	Person-centred care after acute coronary syndrome, from hospital to primary care â€" A randomised controlled trial. International Journal of Cardiology, 2015, 187, 693-699.	1.7	114
67	Type of Atrial Fibrillation and Outcomes inÂPatients With Heart Failure and ReducedÂEjectionÂFraction. Journal of the American College of Cardiology, 2017, 70, 2490-2500.	2.8	114
68	Influenza Vaccination in Patients WithÂChronic Heart Failure. JACC: Heart Failure, 2016, 4, 152-158.	4.1	112
69	Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations. Journal of the American College of Cardiology, 1983, 2, 865-871.	2.8	107
70	Selfâ€assessment of quality of life in severe heart failure: An instrument for clinical use. Scandinavian Journal of Psychology, 1987, 28, 220-225.	1.5	105
71	Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in Patients with Chronic Atrial Fibrillation or Flutter: A Prospective Study. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1044-1057.	1.2	105
72	Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure Patients. Journal of the American College of Cardiology, 2013, 62, 1977-1985.	2.8	104

#	Article	IF	Citations
73	Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure, 2009, 11, 292-298.	7.1	102
74	Influence of Sacubitril/Valsartan (LCZ696)ÂonÂ30-Day Readmission After Heart Failure Hospitalization. Journal of the American College of Cardiology, 2016, 68, 241-248.	2.8	101
75	The past, present and future of reninâ€“angiotensin aldosterone system inhibition. International Journal of Cardiology, 2013, 167, 1677-1687.	1.7	97
76	Age-Related Characteristics and Outcomes of Patients With HeartÂFailure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 601-612.	2.8	97
77	Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network metaâ€analysis. European Journal of Heart Failure, 2018, 20, 1315-1322.	7.1	96
78	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006541.	3.9	96
79	Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart Failure. Circulation, 2002, 105, 1797-1803.	1.6	95
80	Heart rate reduction in cardiovascular disease and therapy. Clinical Research in Cardiology, 2011, 100, 11-19.	3.3	95
81	Dementiaâ€related adverse events in <scp>PARADIGMâ€HF</scp> and other trials in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 129-137.	7.1	95
82	Outcomes and Effect of Treatment According to Etiology in HFrEF. JACC: Heart Failure, 2019, 7, 457-465.	4.1	94
83	Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. European Heart Journal, 2008, 30, 671-678.	2.2	92
84	Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 317-326.	4.1	91
85	Rationale and design of a randomized, doubleâ€blind, placeboâ€controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I_f Inhibitor Ivabradine Trial (SHIFT). European Journal of Heart Failure, 2010, 12, 75-81.	7.1	88
86	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal, 2013, 34, 2263-2270.	2.2	85
87	The prevalence and importance of frailty in heart failure with reduced ejection fractionÂâ€“Âan analysis of <scp>PARADIGMâ€HF</scp> and <scp>ATMOSPHERE</scp>. European Journal of Heart Failure, 2020, 22, 2123-2133.	7.1	85
88	Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure. JAMA Cardiology, 2018, 3, 498.	6.1	84
89	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to) Tj ETQq1 1 0.784314 rgBT /Ov Therapy. Circulation: Heart Failure, 2016, 9, .	3.9	83
90	The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. European Heart Journal, 2013, 34, 2823-2829.	2.2	79

#	Article	IF	Citations
91	Seattle Heart Failure and Proportional RiskÂModels Predict Benefit From ImplantableÂCardioverter-Defibrillators. Journal of the American College of Cardiology, 2017, 69, 2606-2618.	2.8	79
92	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006539.	3.9	78
93	Uncertainty in illness among patients with chronic heart failure is less in person-centred care than in usual care. European Journal of Cardiovascular Nursing, 2013, 12, 521-528.	0.9	77
94	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation, 2015, 131, 43-53.	1.6	75
95	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the <scp>EMPHASISâ€HF</scp> trial. European Journal of Heart Failure, 2017, 19, 1186-1197.	7.1	75
96	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failureâ€"COMET. American Heart Journal, 2005, 149, 370-376.	2.7	74
97	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2019, 140, 1369-1379.	1.6	74
98	Person-centred care for patients with chronic heart failure â€“ a costâ€“utility analysis. European Journal of Cardiovascular Nursing, 2016, 15, 276-284.	0.9	71
99	Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rateâ€lowering properties. European Journal of Heart Failure, 2014, 16, 76-85.	7.1	70
100	Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. European Journal of Heart Failure, 2002, 4, 321-329.	7.1	69
101	Prognostic importance of plasma NTâ€pro BNP in chronic heart failure in patients treated with a Î²â€blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial. European Journal of Heart Failure, 2007, 9, 795-801.	7.1	69
102	Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASISâ€HF). European Journal of Heart Failure, 2010, 12, 617-622.	7.1	66
103	Commentary: Swedish initiative on person centred care. BMJ, The, 2015, 350, h160.	6.0	65
104	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. European Journal of Heart Failure, 2018, 20, 295-303.	7.1	65
105	An eHealth Diary and Symptom-Tracking Tool Combined With Person-Centered Care for Improving Self-Efficacy After a Diagnosis of Acute Coronary Syndrome: A Substudy of a Randomized Controlled Trial. Journal of Medical Internet Research, 2016, 18, e40.	4.3	64
106	Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. European Journal of Heart Failure, 2013, 15, 1296-1303.	7.1	63
107	Income Inequality and Outcomes in HeartÂFailure. JACC: Heart Failure, 2019, 7, 336-346.	4.1	63
108	The Impact of Chronic Obstructive Pulmonary Disease in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction: An Analysis of the EVEREST Trial. Journal of Cardiac Failure, 2012, 18, 515-523.	1.7	62

#	Article	IF	Citations
109	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. European Heart Journal, 2015, 36, 669-675.	2.2	62
110	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). European Journal of Heart Failure, 2018, 20, 760-768.	7.1	62
111	Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. European Journal of Heart Failure, 2009, 11, 92-98.	7.1	61
112	Skeletal muscle characteristics, muscle strength and thigh muscle area in patients before and after cardiac transplantation. European Journal of Heart Failure, 2001, 3, 59-67.	7.1	60
113	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiology, 2020, 5, 432.	6.1	59
114	The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. JACC: Heart Failure, 2013, 1, 488-496.	4.1	58
115	Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in <scp>SHIFT</scp>. European Journal of Heart Failure, 2014, 16, 810-816.	7.1	58
116	Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the <scp>SHIFT</scp> trial. European Journal of Heart Failure, 2015, 17, 1294-1301.	7.1	58
117	Effects of a person-centred telephone-support in patients with chronic obstructive pulmonary disease and/or chronic heart failure â€“ A randomized controlled trial. PLoS ONE, 2018, 13, e0203031.	2.5	58
118	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and HeartÂFailure Cause. JACC: Heart Failure, 2020, 8, 844-855.	4.1	56
119	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovascular Drugs and Therapy, 2017, 31, 545-549.	2.6	55
120	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. Circulation: Heart Failure, 2018, 11, e004745.	3.9	55
121	Twentyâ€fourâ€hour heart rate lowering with ivabradine in chronic heart failure: insights from the <scp>SHIFT</scp> Holter substudy. European Journal of Heart Failure, 2015, 17, 518-526.	7.1	54
122	Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). American Journal of Cardiology, 2015, 116, 1890-1897.	1.6	54
123	The prognostic value of troponin T and Nâ€terminal pro Bâ€type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 2019, 21, 40-49.	7.1	54
124	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal, 2015, 36, 1106-1114.	2.2	53
125	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, .	3.9	53
126	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	3.9	53

#	Article	IF	Citations
127	Length of hospital stay and 30â€day readmission following heart failure hospitalization: insights from the <scp>EVEREST</scp> trial. European Journal of Heart Failure, 2015, 17, 1022-1031.	7.1	52
128	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circulation: Heart Failure, 2016, 9, .	3.9	52
129	Contribution of cardiac and extraâ€cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. European Journal of Heart Failure, 2018, 20, 504-510.	7.1	52
130	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 2019, 21, 974-984.	7.1	52
131	Treatment of chronic heart failure: a comparison between the major guidelines. European Heart Journal, 2006, 27, 1773-1777.	2.2	46
132	Efficacy and Safety of Ivabradine in Patients With Severe Chronic Systolic Heart Failure (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	45
133	The Evolution of Î²-Blockers in CoronaryÂArteryÂDiseaseÂand HeartÂFailureÂ(Part 1/5). Journal of the American College of Cardiology, 2019, 74, 672-682.	2.8	44
134	Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction. Circulation: Heart Failure, 2014, 7, 895-902.	3.9	43
135	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials ofÂHeart Failure. JACC: Heart Failure, 2018, 6, 564-569.	4.1	43
136	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASISâ€HF trial. European Journal of Heart Failure, 2019, 21, 345-351.	7.1	43
137	Risk following hospitalization in stable chronic systolic heart failure. European Journal of Heart Failure, 2013, 15, 885-891.	7.1	42
138	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from <scp>SHIFT</scp>. European Journal of Heart Failure, 2014, 16, 426-434.	7.1	42
139	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: REDâ€HF study. European Journal of Heart Failure, 2018, 20, 268-277.	7.1	42
140	Effectiveness of person-centred care after acute coronary syndrome in relation to educational level: Subgroup analysis of a two-armed randomised controlled trial. International Journal of Cardiology, 2016, 221, 957-962.	1.7	41
141	Achieving a Maximally Tolerated Î²-Blocker Dose in Heart Failure Patients. Journal of the American College of Cardiology, 2017, 69, 2542-2550.	2.8	41
142	Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure, 2018, 20, 373-381.	7.1	41
143	Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a postâ€hoc analysis of <scp>SHIFT</scp>. European Journal of Heart Failure, 2016, 18, 1182-1189.	7.1	39
144	Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model. International Journal of Cardiology, 2015, 184, 163-169.	1.7	38

#	Article	IF	Citations
145	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 1226.	6.1	38
146	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 2019, 21, 577-587.	7.1	38
147	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). American Journal of Cardiology, 2015, 115, 790-796.	1.6	37
148	Heart rate and its reduction in chronic heart failure and beyond. European Journal of Heart Failure, 2017, 19, 1230-1241.	7.1	37
149	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. European Heart Journal, 2017, 38, ehw509.	2.2	36
150	Effects of person-centred care after an event of acute coronary syndrome: Two-year follow-up of a randomised controlled trial. International Journal of Cardiology, 2017, 249, 42-47.	1.7	36
151	Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy. Circulation: Heart Failure, 2013, 6, 711-718.	3.9	35
152	Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. European Journal of Heart Failure, 2015, 17, 1201-1207.	7.1	35
153	Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction. Circulation, 2016, 134, 1785-1787.	1.6	35
154	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGMâ€HF. European Journal of Heart Failure, 2018, 20, 514-522.	7.1	35
155	Incidence and Outcomes of Pneumonia in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1961-1973.	2.8	35
156	Acute Myocardial Infarction: Difference in the Treatment between Men and Women. International Journal for Quality in Health Care, 1993, 5, 261-265.	1.8	34
157	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2014, 7, 401-408.	3.9	34
158	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American Heart Journal, 2017, 188, 35-41.	2.7	32
159	Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 399-407.	4.1	31
160	Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. European Journal of Heart Failure, 2000, 2, 229-233.	7.1	30
161	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. European Heart Journal, 2015, 36, 2310-2317.	2.2	30
162	Successful treatment of heart failure with devices requires collaboration. European Journal of Heart Failure, 2008, 10, 1229-1235.	7.1	29

#	Article	IF	Citations
163	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 528-538.	7.1	28
164	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	26
165	Effect of Combining Ivabradine and Î²-Blockers: Focus on the Use of Carvedilol in the SHIFT Population. Cardiology, 2015, 131, 218-224.	1.4	25
166	Optimizing the Management of Heart Failure With Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF). Journal of Cardiac Failure, 2016, 22, 539-544.	1.7	25
167	QRS Amplitudes, QTc Intervals and ECG Abnormalities in Pheochromocytoma Patients before, during and after Treatment. Acta Medica Scandinavica, 2009, 224, 231-235.	0.0	24
168	Impact of deviceâ€guided slow breathing on symptoms of chronic heart failure: a randomized, controlled feasibility study. European Journal of Heart Failure, 2011, 13, 1000-1005.	7.1	24
169	Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 79-84.	7.1	24
170	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (REDâ€HF). European Journal of Heart Failure, 2013, 15, 334-341.	7.1	24
171	Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction. American Journal of Medicine, 2015, 128, 1102-1108.e6.	1.5	24
172	Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial. PharmacoEconomics - Open, 2019, 3, 495-504.	1.8	23
173	Effect of Enalapril on Mortality in Congestive Heart Failure. Drugs, 1990, 39, 49-52.	10.9	22
174	Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. European Journal of Heart Failure, 2013, 15, 1044-1052.	7.1	22
175	Insufficient reduction in heart rate during hospitalization despite betaâ€blocker treatment in acute decompensated heart failure: insights from the ASCENDâ€HF trial. European Journal of Heart Failure, 2017, 19, 241-249.	7.1	22
176	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure, 2016, 18, 672-683.	7.1	21
177	Hemodynamic Effects of the Cardioselective Î²â€Blocking Agent Metoprolol in Acute Myocardial Infarction. Acta Medica Scandinavica, 1978, 204, 195-201.	0.0	20
178	Effect of Visitâ€toâ€Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the I _f Inhibitor Ivabradine Trial (SHIFT) Trial. Journal of the American Heart Association, 2016, 5, .	3.7	20
179	Health-care improvements in a financially constrained environment. Lancet, The, 2016, 387, 646-647.	13.7	20
180	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 418-427.	4.1	20

#	Article	IF	Citations
181	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGMâ€HF. Journal of the American Heart Association, 2021, 10, e019238.	3.7	20
182	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the <scp>PARADIGMâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 1518-1524.	7.1	20
183	Effect of sacubitril/valsartan on investigatorâ€reported ventricular arrhythmias in <scp>PARADIGMâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 551-561.	7.1	20
184	Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. European Journal of Heart Failure, 2017, 19, 449-456.	7.1	19
185	Challenges to Data Monitoring Committees When Regulatory Authorities Intervene. New England Journal of Medicine, 2016, 374, 1580-1584.	27.0	17
186	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. European Journal of Heart Failure, 2017, 19, 718-727.	7.1	17
187	Measuring shortness of breath in heart failure (SOBâ€HF): development and validation of a new dyspnoea assessment tool. European Journal of Heart Failure, 2011, 13, 838-845.	7.1	16
188	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	15
189	Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. Cardiology, 2017, 136, 138-144.	1.4	15
190	Post hoc analyses of SHIFT and PARADIGMâ€HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: â€œSafety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trialâ€•by Bocchi et al.. ESC Heart Failure, 2018, 5, 1069-1071.	3.1	15
191	Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. British Journal of Clinical Pharmacology, 2001, 51, 35-43.	2.4	14
192	Prevalence and incidence of intraâ€ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGMâ€HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2370-2379.	7.1	14
193	<scp>Angiotensinâ€“neprilysin</scp> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 2022, 24, 1591-1598.	7.1	14
194	Assessment of Quality of Life in Clinical Trials. Acta Medica Scandinavica, 1986, 220, 1-3.	0.0	13
195	Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure). Circulation: Heart Failure, 2018, 11, e004431.	3.9	13
196	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. Circulation: Heart Failure, 2021, 14, e008052.	3.9	13
197	Effects of Person-Centered Care Using a Digital Platform and Structured Telephone Support for People With Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: Randomized Controlled Trial. Journal of Medical Internet Research, 2021, 23, e26794.	4.3	13
198	Effects on Mortality during Five Years after Early Intervention with Metoprolol in Suspected Acute Myocardial Infarction. Acta Medica Scandinavica, 1988, 223, 227-231.	0.0	12

#	Article	IF	Citations
199	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the <scp>EMPHASISâ€HF</scp> study. European Journal of Heart Failure, 2016, 18, 1175-1181.	7.1	12
200	Treatment of diabetes and heart failure: joint forces. European Heart Journal, 2016, 37, 1535.2-1537.	2.2	12
201	The effect of treatment on survival in congestive heart failure. Clinical Cardiology, 1992, 15, 323-329.	1.8	11
202	ST Variability during the First 4 Hours of Acute Myocardial Infarction Predicts 1-Year Mortality. Annals of Noninvasive Electrocardiology, 2001, 6, 198-202.	1.1	11
203	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.. ESC Heart Failure, 2019, 6, 1199-1207.	3.1	11
204	Person-centred care by a combined digital platform and structured telephone support for people with chronic obstructive pulmonary disease and/or chronic heart failure: study protocol for the PROTECT randomised controlled trial. BMJ Open, 2020, 10, e036356.	1.9	11
205	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <scp>PARADIGMâ€HF</scp> analysis. European Journal of Heart Failure, 2021, 23, 1346-1356.	7.1	11
206	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. Canadian Journal of Cardiology, 2015, 31, 1282-1292.	1.7	10
207	Effects of personâ€centred care via telephone on selfâ€efficacy in patients with chronic obstructive pulmonary disease: Subgroup analysis of a randomized controlled trial. Nursing Open, 2021, 8, 927-935.	2.4	10
208	Pure heart rate reduction: further perspectives in heart failure. Country Review Ukraine, 2007, 9, F20-F24.	0.8	9
209	Plasma Levels of Platelet Factor 4 in Patients Admitted to a Coronary Care Unit. Scandinavian Journal of Haematology, 1981, 26, 235-240.	0.0	9
210	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGMâ€HF. ESC Heart Failure, 2020, 7, 3355-3364.	3.1	9
211	Implementation of Person-Centered Care: A Feasibility Study Using the WE-CARE Roadmap. International Journal of Environmental Research and Public Health, 2021, 18, 2205.	2.6	9
212	Heart failure subtypes: Pathophysiology and definitions. Diabetes Research and Clinical Practice, 2021, 175, 108815.	2.8	9
213	Testing cost containment of future healthcare with maintained or improved qualityâ€”The <scp>COSTCARES</scp> project. Health Science Reports, 2021, 4, e309.	1.5	9
214	Effects of the Ikr-blocker almokalant and predictors of conversion of chronic atrial tachyarrhythmias to sinus rhythm. A prospective study. Cardiovascular Drugs and Therapy, 1999, 13, 329-338.	2.6	8
215	ADPâ€induced Platelet Aggregation and Metoprolol Treatment of Myocardial Infarction Patients. Acta Medica Scandinavica, 1985, 217, 15-20.	0.0	8
216	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clinical Research in Cardiology, 2021, 110, 1234-1248.	3.3	8

#	Article	IF	Citations
217	Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure - a COMET substudy. Thrombosis Research, 2010, 125, e46-e50.	1.7	7
218	The beat goes on: on the importance of heart rate in chronic heart failure. European Heart Journal, 2012, 33, 1044-1045.	2.2	7
219	From CONSENSUS to SAVE: The Early Development of Inhibition of the Renin-Angiotensin System in the Treatment of Chronic Heart Failure. Journal of Cardiac Failure, 2016, 22, 395-398.	1.7	7
220	Person-centred eHealth intervention for patients on sick leave due to common mental disorders: study protocol of a randomised controlled trial and process evaluation (PROMISE). BMJ Open, 2020, 10, e037515.	1.9	7
221	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in <scp>EMPHASISâ€HF</scp> and <scp>RALES</scp>. European Journal of Heart Failure, 2022, 24, 529-538.	7.1	7
222	Implantable left ventricular assist systems (LVAS): Recent results. A report from a series of meetings sponsored by the Study Group on Advanced Heart Failure of the Working Group on Heart Failure. European Journal of Heart Failure, 2000, 2, 13-18.	7.1	6
223	Who is an author?. European Journal of Heart Failure, 2008, 10, 523-524.	7.1	6
224	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46	1.6	6
225	Effects of a Person-Centered eHealth Intervention for Patients on Sick Leave Due to Common Mental Disorders (PROMISE Study): Open Randomized Controlled Trial. JMIR Mental Health, 2022, 9, e30966.	3.3	6
226	nâ€“3 Fatty Acids in Cardiovascular Disease. New England Journal of Medicine, 2011, 365, 1159-1159.	27.0	5
227	The year in cardiology 2017: heart failure. European Heart Journal, 2018, 39, 832-839.	2.2	5
228	Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. Clinical Research in Cardiology, 2019, 108, 806-814.	3.3	5
229	Use of Nitrates in Acute and Chronic Congestive Heart Failure. Drugs, 1987, 33, 147-149.	10.9	4
230	Another year with heart failure. European Journal of Heart Failure, 2007, 9, 1-1.	7.1	4
231	Possible adrenergic effects on heart protein metabolism. Acta Medica Scandinavica, 1983, 213, 85-93.	0.0	4
232	EFFECTS OF ACEâ€INHIBITION ON REGIONAL CIRCULATION IN CONGESTIVE HEART FAILURE. Acta Medica Scandinavica, 1986, 219, 91-93.	0.0	4
233	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clinical Research in Cardiology, 2021, 110, 1334-1349.	3.3	4
234	Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF. Clinical Research in Cardiology, 2021, 111, 440.	3.3	4

#	Article	IF	Citations
235	Plasma Concentrations of Platelet Factor 4 in Acute Myocardial Infarction. Scandinavian Journal of Haematology, 2009, 26, 359-363.	0.0	3
236	Thoughts from an outgoing Editor-in-Chief. European Journal of Heart Failure, 2010, 12, 3-3.	7.1	3
237	Mixed results for heart failure therapies. Nature Reviews Cardiology, 2015, 12, 73-75.	13.7	3
238	Effect of Ivabradine onÂEarly Readmissions After Hospitalization for Worsening Heart Failure. JACC: Heart Failure, 2015, 3, 268-269.	4.1	3
239	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. Clinical Research in Cardiology, 2021, 110, 1308-1320.	3.3	3
240	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. Circulation: Heart Failure, 2021, 14, e008075.	3.9	3
241	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. American Heart Journal, 2021, 237, 45-53.	2.7	3
242	Exploring New Treatment Strategies in Heart Failure. Blood Pressure, 2000, 9, 44-48.	1.5	2
243	Diagnostic and Therapeutic Algorithms in Chronic Heart Failure. Herz, 2006, 31, 877-880.	1.1	2
244	How to publish in European Journal of Heart Failure â€" what do we want?. European Journal of Heart Failure, 2008, 10, 1-2.	7.1	2
245	Fallacies in clinical cardiovascular trials. Heart, 2009, 95, 1464-1468.	2.9	2
246	Lessons for the monitoring of safety in clinical trials. European Journal of Heart Failure, 2018, 20, 148-148.	7.1	2
247	Awaiting publication - A frustrating period for the scientist and the editor. European Journal of Heart Failure, 2007, 9, 547-547.	7.1	1
248	Response to Letter Regarding Article, â€œInfluence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failureâ€. Circulation, 2008, 118, .	1.6	1
249	Reviewers 2008. European Journal of Heart Failure, 2009, 11, 225-226.	7.1	1
250	Editorial commentary: Guidelines for the treatment of chronic heart failure. Trends in Cardiovascular Medicine, 2017, 27, 324-325.	4.9	1
251	Can beta-blockers be used safely in non-cardiac surgery? Important lessons to be learned. European Heart Journal, 2017, 38, 2429-2430.	2.2	1
252	The clinical practice of treating patients with chronic heart failure needs to be improved. European Journal of Heart Failure, 2021, 23, 1512-1513.	7.1	1

#	Article	IF	Citations
253	Abstract 12794: Hospital Length of Stay and Readmissions Post Heart Failure Hospitalization in the EVEREST Trial. Circulation, 2014, 130, .	1.6	1
254	Conclusions on the management of heart failure.. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, S34.	1.7	0
255	1446 Assessing Dyspnoea in Patients with Chronic Heart Failureâ€"Does Gender Make a Difference?. European Journal of Cardiovascular Nursing, 2005, 4, 65-66.	0.9	0
256	Reviewers 2006. European Journal of Heart Failure, 2007, 9, 109-109.	7.1	0
257	What should we do about heart failure: challenges for 2009. European Journal of Heart Failure, 2009, 11, 1-2.	7.1	0
258	Development of tolerance to nitrate therapy in chronic congestive heart failure. Acta Pharmacologica Et Toxicologica, 1986, 59, 49-51.	0.0	0
259	Optimal Pharmacological Therapy in Chronic Heart Failure 2011 - How to Achieve the Standard. Journal of Cardiac Failure, 2011, 17, S123-S124.	1.7	0
260	Relaxing from dyspnoea. European Heart Journal, 2014, 35, 1017-1018.	2.2	0
261	Diseaseâ€specific health status as a predictor of mortality. European Journal of Heart Failure, 2014, 16, 923-923.	7.1	0
262	Editorial Commentary: The success of heart rate control in the treatment of chronic heart failure. Trends in Cardiovascular Medicine, 2016, 26, 450-451.	4.9	0
263	Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et al.. International Journal of Cardiology, 2017, 239, 2.	1.7	0
264	Abstract 18395: Safety of Continuing Ivabradine Treatment During Hospitalization for Worsening of Heart Failure in the SHIFT Study. Circulation, 2015, 132, .	1.6	0